Caladrius Biosciences (CLBS) Reports Q4 Loss Per Share of 59c, Affirms FY16 Rev. Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Caladrius Biosciences Announces 2015 Fourth Quarter and Full Year Financial Results
March 15, 2016 4:04 PM EDTQuarterly Growth of 43% and Annual Growth of 25% versus Prior Year Driven by PCT Clinical Services Revenues
Conference Call Begins Today at 5:00 pm Eastern Time
BASKING RIDGE, N.J., March 15, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ: CLBS) (Caladrius), a cell therapy company combining an industry-leading development and manufacturing services provider with a select therapeutic development pipeline, announces financial results for the three and twelve months ended December 31, 2015 respectively.
Financial and Business Highlights
Executed a global collaboration and license... More